The novel antibacterial peptide mimetic alaphosphin (L-alanyl-L-1-aminoethylphosphonic acid) selectively inhibited peptidoglycan biosynthesis in both gram-negative and gram-positive bacteria. It induced accumulation of uridine diphosphate-N-acetyl-muramyl-tripeptide in gram-positive organisms and significantly reduced the intracellular pool levels of D-alarnie. Alaphosphin was actively transported into bacterial cells by stereospecific peptide permeases and was subsequently hydrolyzed by intracellular aminopeptidases to yield L-1-aminoethylphosphonic acid. This alanine mimetic rapidly accumulated inside susceptible cells to yield a concentration which was 100-to 1,000-fold in excess of that of the precursor peptide in the surrounding medium. In the case of susceptible gram-negative organisms, it was shown that 1-aminoethylphosphonic acid was incorporated into a metabolite which was tentatively identified as uridine diphosphate-N-acetylmuramyl-aminoethylphosphonate. The primary intracellular target site of 1-aminoethylphosphonic acid was alanine racemase (EC 5.1.1.1), which was reversibly and competitively inhibited in the gram-negative organisms Escherichia coli and Pseudomonas aeruginosa and irreversibly inhibited in a time-dependent manner in the gram-positive organisms Staphylococcus aureus and Streptococcus faecalis. A secondary target site could be uridine diphosphate-N-acetylmuramyl-L-alanine synthetase [EC 6.3.2.8(b)]. The mechanism of action of alaphosphin may be regarded as involving at least three stages: (i) active transport by peptide permeases; (ii) intracellular peptidase cleavage; and (iii) action of L-1-aminoethylphosphonate on alanine racemase.
tive transport and metabolism data were obtained by using Enterobacter cloacae R 1398, Serratia marcescens S 42, and Klebsiella aerogenes NCTC 816. Organisms were routinely grown under aerobic conditions at 37°C in a defined peptide-free medium (5) . The concentrations of lysine and valine supplements were adjusted for studies involving labeled amino acid incorporation into cells. Streptococcus faecalis NCIB 6457 was used as a source of isolated enzymes after growth in Oxoid Todd-Hewitt broth.
Incorporation oflabeled precursor into wholecell peptidoglycan and protein fractions. Cell wall and protein biosyntheses were measured in E. coli by following the incorporation at 37°C of into trichloroacetic acid-insoluble material. Samples (0.5 ml) of an exponentially growing culture (2 x 108 to 3 x 108 cells per ml) were added to flasks containing labeled precursor and inhibitor in 4.5 ml of defined medium. Samples (0.5 ml) were taken at intervals and precipitated with 2 ml of 10% (wt/vol) trichloroacetic acid at 0°C for 15 min. The precipitates were filtered on Whatman 2.5-cm glass fiber disks (type GF/C), washed twice with 2 ml of ice-cold 5% (wt/vol) trichloroacetic acid and twice with 5 ml of 1% (vol/vol) acetic acid, and dried, and the radioactivity was measured in a Packard Tricarb liquid scintillation spectrometer, using a toluene-based scintillation fluid containing 4 g of 2,5-bis(5'-tert-butylbenzoxazolyl-2')-thiophene per liter. The concentration of labeled amino acids was adjusted to give linear incorporation of radioactivity during a 30-min incubation. To measure the specific incorporation of diaminopimelic acid into peptidoglycan, 200,ug of lysine per ml was added to the incubation mixture, and the concentration of aspartate in the medium was reduced. Peptidoglycan and protein biosyntheses in S. aureus were both followed by using 1 pCi of L- [4,5-3H] lysine (37 mCi/mmol) per ml and employing a selective pronase method to distinguish the fractions (6) .
Isolation and characterization of cell wall precursor UDP-muramyl peptides. Mid-to late-exponential-phase cultures of S. aureus were washed and preincubated for 15 min in the defined medium at 37°C to allow cells to recover, and 100-ml portions (5 x 108 bacteria per ml) were incubated for 90 min at 37°C with cell wail inhibitor at the concentrations indicated below. After incubation, the cells were harvested by centrifugation and resuspended in 5 ml of distilled water. The cell contents were released by heating at 100°C for 5 min, the precipitated material was removed by centrifugation, and the N-acetylhexosamine content was determined (24) . Nucleotide-muropeptide precursors were separated from cell extracts by either charcoal adsorption (20 mg/,umol of nucleotide) followed by elution with water-NH3-ethanol (50:0.3:50) (14) or by ion-exchange chromatography on Dowex 1 (Cl-; AG1-X2) using a linear gradient of 0.01 to 0.4 M NaCl in 0.01 N HCl. After desalting on Sephadex G10 where necessary, the nucleotide fractions were further separated and characterized by descending chromatography on Whatman no. 1 paper in isobutyric acid-i M ammonia (5:3, vol/vol) for 3 days and by high-voltage paper electrophoresis at pH 1.8 (4% [vol/vol] formic acid) for 30 to 60 min at 100 V/cm, using a Shandon model L-24 electrophoresis apparatus. Muropeptides were located on paper by ultraviolet absorption scanning and autoradiography. Radioactivity was quantitatively determined by scintillation counting of 1-cm strips.
Standard muropeptide precursors were obtained from S. aureus as follows: uridine diphosphate-N-acetylmuramic acid (UDP-NAMA) was obtained by novobiocin treatment (33) ; UDP-NAMA-Ala was obtained by enzymic addition of L-['4C]alanine to UDP-NAMA (14) ; UDP-NAMA-tripeptide was obtained by D-cycloserine treatment; and UDP-NAMA-pentapeptide was obtained by vancomycin treatment (14) .
Muropeptide precursor molecules were chemically identified by amino acid and hexosamine analysis and by Fourier-transform nuclear magnetic resonance.
Amino acid analysis was carried out after acid hydrolysis of freeze-dried material in 50 pl of 4 N HCl at 120°C for 8 h. The hydrolysate was made up to 4 ml with water, and 0.8-ml samples (containing 0.05 to 0.1 ,umol of hexosamine) were applied directly to a JEOL LJC-6AH amino acid analyzer.
Measurement of intracellular D-and L-alanine pool levels. Mid-to late-exponential-phase cultures were harvested, washed, and resuspended in 20 ml (S. aureus) or 100 ml (E. coli, Pseudomonas) of prewarmed medium at a cell density of 3 x 108 to 4 x 108 bacteria per ml. After incubation with inhibitor for 15 to 120 min at 37°C, the cells were harvested by centrifugation and washed with 0.9% (wt/vol) NaCl prewarmed to 30°C. The cells were finally resuspended in 3.3 ml of 0.1 M phosphate buffer (pH 7.0), and their contents were released by heating at 100°C for 10 min. After cooling in ice, the suspension was centrifuged, and the supernatant was divided into two 1.5-ml aliquots. Amounts of D-and L-alanine were determined by using the D-amino acid oxidase method of Manning et al. (20) , followed by amino acid analysis. Intracellular concentrations were calculated by using a cell volume based on 2.7 p1/mg of cell dry weight.
Transport and metabolism of alaphosphin.
Early-to mid-exponential-phase cultures of E. coli were harvested, washed, and resuspended in 10 ml of defined medium or Davis minimal medium (7) at 37°C at a cell density of 1.5 x 108 to 3 x 108 bacteria per ml. After a 10-min preincubation to allow cells to recover, 100 pLM ['4C]alaphosphin [7. 6 mCi/mmol; labeled in the Ala(P) moiety] was added to the 10-ml cultures, and 1-ml samples were taken at intervals and centrifuged, and the cells were resuspended in 0.1 ml of water. The cell contents were extracted from the 0.1-ml samples by heating them to 100°C for 5 min. After centrifugation in an Eppendorf microcentrifuge, 10-pl samples of the supernatants were applied to Whatman no. 1 paper (presoaked in 4% formic acid, pH 1.8) , and alaphosphin was separated from its metabolites by high-voltage electrophoresis (100 V/cm) as described above for muropeptides.
Total uptake of ['4C]alaphosphin was determined by using the same 10-ml cultures as above. Samples (0.5 ml) were taken at intervals, and the cells were harvested by rapid filtration by using Whatman GF/C filter disks. The filters were washed twice with 5 ml of 0.9% (wt/vol) NaCl at 20°C and dried, and the radioactivity was determined by liquid scintillation counting. Transport studies were also carried out in the presence of D-alanine, peptides, or uncoupling agents or by using alaphosphin which was labeled with 14C in the L-alanine moiety (0.22 mCi/mmol) or the L-Ala(P) moiety (7.6 mCi/mmol). In comparative experiments specific activities were normalized to 0.2 mCi/mmol. Intracellular levels of unlabeled alaphosphin and its metabolite Ala(P) were determined by amino acid analysis as described previously (5) .
Metabolite M was isolated from E. coli and identified as described above for muropeptide precursors. E. coli cultures (100 ml) at a cell density of 5 Preparation and assay of alanine racemase. Alanine racemase (EC 5.1.1.1) was prepared from lateexponential-phase cultures of E. coli and S. faecalis (109 bacteria per ml) by using a method similar to that described by Lambert and Neuhaus (18) . The 40 to 60% saturated (NH4)2SO4 precipitate was dissolved in 50 mM phosphate buffer (pH 7.4) and desalted by passing through Sephadex G50. This crude racemase preparation was stored at 40C and assayed as follows. After a 10-min incubation at 370C with 1 to 40 mM Lalanine in 1 ml of 50 mM phosphate buffer (pH 7.4), the reaction was stopped by boiling for 2 min, and the precipitated material was removed by rapid centrifugation in an Eppendorf microcentrifuge. The amount of D-alanine formed was determined colorimetrically by mixing the supernatant with 0.5 ml of a solution containing 1 mg of phenol per ml and 10 mg of KH2PO4, pH 5.0, per ml and adding 0.5 ml of the mixture to 0.5 ml of a solution containing 10 
were prepared from S. faecalis and E. coli and assayed by using previously described methods (14, 19, 21) .
RESULTS
Effect on macromolecular synthesis. The effect of alaphosphin on macromolecular synthesis in E. coli was measured by following the incorporation of radiolabeled diaminopimelic acid and valine into cell wall and protein fractions, respectively. Inhibition of cell wall biosynthesis occurred before effects on protein biosynthesis ( with S. aureus, using the incorporation of lysine into protease-sensitive and protease-resistant cell fractions as indicators of protein and cell wall biosynthesis (6), respectively, although higher levels of alaphosphin were necessary; e.g., 50% inhibition of peptidoglycan biosynthesis after 10 min required more than 100 lg of alaphosphin per ml. Since alaphosphin had no influence on the incorporation of [3H]uridine or [3H]thymidine during the first 10 min of the incubation, it was concluded that nucleic acid biosynthesis was unaffected in both organisms.
Accumulation of peptidoglycai? precursors. Of the various susceptible organisms which were examined, S. aureus produced the greatest amount ofN-acetylhexosanine-positive material in response to cell wall inhibitory agents. In particular, S. aureus R 2192 yielded 48, 33, and 8 nmol of hexosamine per ml of culture after 90 min of incubation with 10-,g/ml concentrations of D-cycloserine, vancomycin, and penicillin G, respectively. Incubation of cells with alaphosphin, at an optimal concentration of 5 ,ug/ml (25 AM), resulted in the accumulation of 17 nmol of hexosamine per ml of culture under the same conditions (Fig. 2) . Accumulation of peptidoglycan precursors was also dependent on growth conditions, incubation time, and the strain of S. aureus used. Under suboptimal conditions as little as 3 nmol of hexosamine per ml of culture was produced in response to alaphosphin. It is interesting to note that alaphosphin Cell wall nucleotides were isolated by using either charcoal elution or Dowex ion-exchange chromatography, and they were characterized by amino acid hydrolysis, electrophoresis, and isobutyric acid-NH3 paper chromatography. The major products of novobiocin, D-cycloserine, and vancomycin treatment were characteristically (14) UDP-NAMA and the muramyl triand pentapeptides, respectively, with electrophoretic mobilities of 24, 9.5, and 8 cm. Under optimal concentrations of alaphosphin (i.e., 5 ,ug/ml), the (Fig. 3a) . After 20 to 30 min of incubation in defined medium, cell lysis occurred (as determined by a decrease in turbidity), and radioactivity was released into the medium. Transport was not inhibited by preincubation of cells with 10 jig of chloramphenicol per ml, but it was rapidly inhibited by proton-conducting uncoupling agents, e.g. carbonyl cyanide p-trifluoromethoxyphenylhydrazone (Fig. 3c) . Incubation of E. coli in the absence of an energy source (e.g., glucose) also led to a reduced rate of alaphosphin transport.
All-L di-and tripeptides were potent inhibitors of alaphosphin transport, as shown in Fig. 3a for di-and trialanine. All-L tetraalanine and dipeptides containing D residues did not compete at equimolar concentrations relative to alaphosphin.
The percent uptake of alaphosphin from the medium depended on drug concentration and cell density. At an alaphosphin concentration of 100 ,uM (20 ,ug/ml) and in the presence of 3 x 108 bacteria per ml (i.e., the conditions in Fig.  3a) , 29% of drug was transported into the cells in 15 min. However, at drug concentrations less than 1 utg/ml, uptake levels approached 100% (Table 3) .
Addition of 500 uM D-alanine at the beginning of the incubation did not inhibit alaphosphin transport but did prevent release ofradioactivity after 30 min (Fig 3a) . In contrast to the alaphosphin peptide, '4C-labeled L-Ala(P) was not significantly taken up by any of the organisms examined at concentrations of s mM (Fig. 3b) . Transport of alaphosphin in Davis minimal medium without amino acid supplement was similar to that in the defined medium, but cell lysis, as determined by the decrease in turbidity, and release of radioactivity did not occur within 60 min. (Fig. 3c) .
Cellular accumulation of radioactivity from alaphosphin labeled in the L-alanine moiety was significantly less than that from alaphosphin labeled in the Ala(P) moiety. The release of radioactivity during lysis was also slower (Fig.   3b ). This suggests that ["4C]alanine liberated from alaphosphin within the cell could either be used for biosynthetic reactions or effluxed from the cell, possibly via an amino acid permease.
Metabolism of alaphosphin. Electrophoresis of the cell contents after uptake of alaphosphin revealed that Ala-['4C]Ala(P) was rapidly hydrolyzed to produce the Ala(P) moiety (Fig.  4) . Intact alaphosphin was detectable inside cells, and it increased for the first 5 to 10 min, achieving a concentration of 40 to 50 times that of the initial extracellular concentration. However, while alaphosphin accumulated inside the cell, metabolism occurred to release Lalanine and the Ala(P) moiety. When sufficient extracellular alaphosphin was available, Ala(P) accumulated inside the cells until a level of 30 to 40 mM was achieved. The concentration of intracellular Ala(P) exceeded the initial extracellular concentration of alaphosphin by 1,200 to 84 times in the range of 1 to 500 ,uM alaphosphin (Table 3 ).
An additional metabolite, comprising up to 20% of the total intracellular radioactivity (Fig.  4) , was also identified after a 10-to 15-min tents were separated by high-voltage paper electrophoresis at pH 1.8 (Fig. 5b) , and the radioactivity associated with Ala-Ala(P), Ala(P), and the metabolite ofAla(P), i.e. compound M, was measured.
incubation of E. coli cells with alaphosphin. This metabolite (metabolite M) was isolated by Dowex ion-exchange chromatography and paper electrophoresis (pH 1.8) (Fig. 5) . The electrophoretic mobility of metabolite M, which ran in the region of UDP-NAMA and UDP-NAMAAla, was consistent with its being a muramylnucleotide intermediate. By gel filtration chromatography on Sephadex G10 and Biogel P2, metabolite M appeared to have a molecular weight between 500 and 1,000, and on acid hydrolysis it yielded Ala(P).
Cells incubated with alaphosphin labeled in the N-terminal alanine moiety did not produce labeled metabolite M. Other susceptible gramnegative organisms (Serratia, Klebsiella, Salmonella) also produced metabolite M, but it was not detected in significant amounts in any of the susceptible gram-positive organisms tested (S. aureus, S. faecalis) ( trophoretic mobility close to that of metabolite M. Inhibition of alanine racemase. Alanine racemase was assayed in all cases in the anabolic direction (i.e., L to D). Against the E. coli enzyme (Km, 0.93 X 10-3 M), L-Ala(P) was shown to be a potent competitive inhibitor, with a Ki of 30 ,IM. D-Cycloserine also exhibited competitive inhibition kinetics, with a Ki of 650 ,uM. The ratios of Km to Ki for L-Ala(P) and D-cycloserine were, therefore, 30 and 1.4, respectively.
L-Ala(P) inhibition of the racemase from S.
faecalis was, however, a time-dependent process which was apparently irreversible and followed pseudo-first order rate kinetics of inactivation (Fig. 6b) . The rate of inactivation was reduced in the presence of the substrate L-alarmlne, but passage of the inhibited enzyme through Sephadex G50 or overnight dialysis at 4°C did not restore activity. L-Ala(P) inhibition ofS. faecalis enzyme could not be substantially reversed by subsequent incubation with 1 mM L-alanine or pyridoxal phosphate. The pseudo-first order rate constants for inactivation at 1 and 5 mM Ala(P) under the conditions described in the legend to respectively. S. aureus racemase was irreversibly inhibited by Ala(P) in a manner similar to that observed for the S. faecalis enzyme (data not shown). Inhibition of E. coli and Pseudomonas racemases was not time dependent under the conditions used and was reversed by passage through Sephadex G-50.
Other cell wall enzymes were tested for inhibition by L-Ala(P) and alaphosphin, e.g. D-Ala-D-Ala synthetase, D-Ala-D-Ala adding enzyme, UDP-NAMA-L-Ala synthetase, and UDP-NAMA-L-Ala-D-Glu synthetase. With the exception of UDP-NAMA-L-Ala synthetase, all were insensitive (Table 5) . L-Ala(P) inhibition of this enzyme was competitive but weak, with a Ki of 3 mM and a ratio of Km to Ki of 0.1 for E.
coli. Although D-Ala(P) was inactive against UDP-NAMA-L-Ala synthetase, it did show inhibitory activity against D-Ala-D-Ala synthetase. DISCUSSION The results which have been described established that alaphosphin selectively inhibits bacterial cell wall biosynthesis. Several points of evidence indicate that this inhibition was due to the intracellular action of L-Ala(P). The lowering of the cellular level of the D-alanine pool was consistent with the inhibition of the isolated cell wall enzyme alanine racemase by L-Ala(P). There was inhibition of amino acid incorporation into peptidoglycan fractions and accumulation of UDP-NAMA-tripeptide in gram-positive organisms which could be attributed to the reduced availability of D-alanme. The weaker effect of L-Ala(P) on isolated UDP-NAMA-LAla synthetase appeared to be less important but did account for the presence of UDP-NAMA in the nucleotide-hexosamine fraction at higher alaphosphin concentrations. These results are therefore in accord with earlier observations of spheroplast formation and D-alanxne antagonism (3) . Table 5 . c Inact., Inactive at 10 mM. mediated process. Moreover, once inside the cell, alaphosphin was rapidly cleaved by intracellular LL-specific aminopeptidases to release the active moiety L-Ala(P). Since the influx of carrier peptide exceeded efflux of Ala(P), high intracellular levels of Ala(P) were achieved (40 mM), such that potent inhibition of alanine racemase occurred even in the presence of intracellular amino acids. This intracellular cleavage of alaphosphin was inhibited by the aminopeptidase inhibitor bestatin (29; manuscript in preparation).
Earlier studies have demonstrated the broad specificity of the bacterial peptide permease system relative to that of the amino acid permeases (4, 9) . The organisms investigated in this study did not readily take up Ala(P), although others have observed aminophosphonic acid transport in Pseudomonas (17), S. faecalis, lactobacilli (13) , and, in particular, Bacillus cereus (27) , which utilizes an inducible permease for 2-aminoethylphosphonic acid.
The role played by metabolite M [tentatively identified as UDP-NAMA-L-Ala(P)] in the mechanism of alaphosphin action in gram-negative organisms is uncertain. The proposed structure of metabolite M would, however, also account for inhibition of formation of the muramyl pentapeptide. The absence of significant formation of compound M in gram-positive organisms could be attributed either to enzyme specificity differences or to the much greater pool levels of alanine (30) . The dual effect of LAla(P) on UDP-NAMA-L-Ala synthetase as both a weak inhibitor and a false substrate is similar to that reported for glycine (11) . Other forms of bacterial metabolism of related aminophosphonic acids have been observed (12) , in particular transamination to give the corresponding reactive ketoacids (26) . This type of metabolism was not observed with L-Ala(P) (26) .
Results in this study have indicated differences in the way in which L-Ala(P) inhibited racemases from gram-negative and gram-positive organisms. The reversible nature of the inhibition of E. coli and Pseudomonas racemases by L-Ala(P) contrasts with the slow irreversible inhibition of S. aureus and S. faecalis racemases. Others have also observed reversible inhibition for a variety of alanine mimetics (1, 18) , but recent results suggest that some of these compounds can act as irreversible active sitedirected inhibitors of the E. coli enzyme (31) . The irreversible action of L-Ala(P) may be due to the affinity of aminophosphonic acids for the racemase cofactor pyridoxal phosphate (1) . The possibility of there being fundamental differences between the binding sites on gram-negative and gram-positive racemases has been discussed by others (18) and may be pertinent to the action of alaphosphin in different organisms.
Compared with other inhibitors of alanine racemase (e.g. D-fluoroalanine [31] , D-chloroalanine [20] , D-cycloserine [18] , alaphosphin was more potent in decreasing D-alanine pool levels. This may be due in part to the much more rapid initial rate of alaphosphin uptake (10 would be expected to adversely influence Ala(P) action more in gram-positive organisms because of their greater amino acid pool size (30) . The simultaneous release of equimolar amounts of Lalanine with L-Ala(P) during intracellular hydrolysis of alaphosphin did not produce "internal antagonism," possibly because of the role of amino acid efflux in controlling intracellular amino acid concentrations.
A number of factors, therefore, distinguish the action of alaphosphin in gram-negative and gram-positive organisms; these include rate of uptake, rate of intracellular cleavage, size of the alanine pool, formation of metabolite M, and the mechanism of racemase inhibition. The low activity observed against certain strains of streptococci and Pseudomonas (3) was, however, almost entirely due to poor transport. Double blockade of D-alamnie utilization by combinations of alaphosphin and D-cycloserine has been shown to produce synergy (3); whether this is due to sequential blockade of the racemase and synthetase enzymes or to double inhibition of the racemase has yet to be determined. The synergy observed with alaphosphin and certain ,B-lactam antibiotics may also involve a double block on the availability of Dalanine, since inhibitors of cell wall transpeptidase and carboxypeptidase would prevent any re-utilization of D-alanine released during peptidoglycan cross-linking (10) (Fig. 7) . D-Cycloserine also blocks D-alanine transport (32) , and other inhibitors of racemase are known to potentiate penicillin (28) . The lytic enhancement effect observed with alaphosphin and glycine may also be related to this phenomenon. In summary, alaphosphin is a novel actively transported peptide mimetic which inhibits the early intracellular stages of cell wall biosynthesis. In this respect it resembles fosfomycin (15) and D-cycloserine (21) , but it is unlike other cell wall antibiotics, e.g. penicillin (10) and vancomycin (23), which are not transported and which inhibit later stages of peptidoglycan polymerization. Activity of alaphosphin depends on intracellular metabolism to release an active moiety, and in this respect it belongs to a class of related di-and tripeptide antibiotics, e.g. bacilysin (16) and phosphinothricyl-alanyl-alanine (8) , which act as "warhead" delivery systems (25) . Since the completion of this paper, "alafosfalin" has been adopted as the British Approved Name and the Proposed International Non-Proprietary Name for "alaphosphin."
